Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a biopharmaceutical company dedicated to transforming the treatment of rare diseases through the development and commercialization of innovative therapeutics. The company operates primarily through the development and marketing of approved medicines and clinical-stage… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Mirum Pharmaceuticals, Inc. does
In the company’s own words
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a biopharmaceutical company dedicated to transforming the treatment of rare diseases through the development and commercialization of innovative therapeutics. The company operates primarily through the development and marketing of approved medicines and clinical-stage product candidates targeting rare and orphan diseases with significant unmet medical needs.
Mirum's approved medicines include Livmarli (maralixibat), an orally administered ileal bile acid transporter inhibitor approved for treating cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis; Cholbam (cholic acid), approved for bile acid synthesis disorders and peroxisomal disorders; and Ctexli (chenodiol), approved for cerebrotendinous xanthomatosis. The company commercializes these medicines in the United States, Canada, and select European markets through its specialized commercial team, while also maintaining license and distribution agreements with rare disease companies for additional territories.
The company's clinical pipeline includes volixibat, an oral IBAT inhibitor in Phase 2b development for primary sclerosing cholangitis and primary biliary cholangitis; brelovitug, a fully human monoclonal antibody acquired through the January 2026 acquisition of Bluejay Therapeutics for treating chronic hepatitis D virus infection; and MRM-3379, a PDE4D inhibitor in Phase 2 development for fragile X syndrome.
Mirum's business model centers on identifying, acquiring, and advancing therapeutic candidates for rare diseases where patient populations are limited but medical needs are substantial. The company leverages its expertise in cholestatic liver diseases and rare genetic disorders to build a focused pipeline addressing conditions with limited treatment options. Through strategic acquisitions including the 2023 Bile Acid Portfolio Acquisition from Travere Therapeutics and the 2026 Bluejay Acquisition, Mirum has expanded its product portfolio and clinical capabilities.
The company maintains intellectual property protection through patent portfolios covering its lead compounds, with key patents expiring in October 2032. Mirum's strategy emphasizes efficient resource deployment to maximize long-term value creation through successful commercialization of approved medicines and development of clinical-stage candidates. The company website is www.mirumpharma.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- FOSTER CITY, CA
- Fiscal year end
- December
- CIK
- 1759425
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Mirum Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Mirum Pharmaceuticals, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Mirum Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Mirum Pharmaceuticals, Inc.’s bonds, as funds hold them
Funds report holding 2 issues of Mirum Pharmaceuticals, Inc.’s debt, $126.32M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.20%, maturing 2029 to 2032.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Mirum Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Mirum Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Mirum Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”